News

Jim Cramer Says Biohaven (BHVN) Is “Too Cheap” and He’s a Buyer at $21
We recently published a list of Jim Cramer Recently Talked About These 15 Stocks. In this article, we are going to take a ...
Royalty Pharma (NasdaqGS:RPRX) Declares US$0.22 Dividend for Q2 2025
Royalty Pharma (NasdaqGS:RPRX) recently affirmed its dividend, setting it at $0.22 per Class A ordinary share for the second quarter of 2025, demonstrating its financial stability and commitment to ...
Royalty Pharma price target raised to $42 from $41 at BofA
BofA raised the firm’s price target on Royalty Pharma (RPRX) to $42 from $41 and keeps a Buy rating on the shares. The firm, in its preview of ...
Bank of America Securities Reaffirms Their Buy Rating on Royalty Pharma (RPRX)
In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Royalty Pharma (RPRX – Research Report), ...